Extension study of vitamin supplements for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study looks at continuing a nicotinamide/pterostilbene supplement in people with ALS who already finished an earlier related NO-ALS study. It may help researchers learn whether the supplement can be continued safely and potentially benefit longer-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You already took part in the earlier NO-ALS study and finished it
- You can join whether you were in either treatment group from the earlier study
- You do not have dementia or frontotemporal dementia that would make it hard to follow the study plan
- You do not have another serious illness that would limit your ability to participate
- You are not tracheostomized as part of ALS treatment
- You have not been taking vitamin B3 or blueberry extract outside the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This trial tests a very high-calorie, fatty diet to see if it helps people with ALS. If you have been diagnosed recently and are not too advanced in the disease, this special diet may give your body extra energy to slow progression.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.